Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

Genentech begins phase II trial of DNIB-0600A

Dec. 5, 2013

OncoMed and Celgene sign agreement for anti-cancer stem cell product candidates

Dec. 5, 2013

Alphavirus-based vaccine encoding PSA tested in mouse model of prostate cancer

Dec. 4, 2013

FDA clears California Stem Cell's application for phase III cancer stem cell trial

Dec. 4, 2013

Celldex Therapeutics initiates study of glembatumumab vedotin for triple-negative breast cancer

Dec. 4, 2013

Immunotherapeutic 3M-052 shows oncolytic potential

Dec. 3, 2013

ARMO BioSciences begins phase I study of AM-0100 in advanced solid tumors

Nov. 29, 2013

Immatics presents preliminary phase I results for the novel cancer vaccine IMA-950

Nov. 29, 2013

SillaJen to acquire Jennerex

Nov. 29, 2013

Genmab reaches milestone in Janssen Biotech collaboration

Nov. 27, 2013

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 2, 2026.
AND-017 increases RBC and hemoglobin in sickle cell disease
BioWorld Science
Sickle cell disease (SCD) is an inherited hemoglobinopathy caused by a mutation in the gene encoding β-globin that results in hemoglobin S polymerization, red...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...